Ubiquitin News and Research

RSS

Ubiquitin is a small regulatory protein that has been found in almost all cells (''ubiquitously'') with nuclei (eukaryotes). It directs proteins to recycling and other functions.

Alzheimer’s and Parkinson’s linked to aging brain’s failing waste disposal

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other neurodegenerative diseases—offering hope for targeted therapies to slow or prevent these conditions.

30 Jan 2025

How your immune system ages: Scientists reveal key changes over a lifetime

Scientists mapped how the human immune system evolves from birth to old age, revealing key changes that influence health, disease resistance, and aging. Their immune age model could help predict immune health and guide early interventions.

30 Jan 2025

Pomalidomide shows promise in enhancing immune responses in myeloma

A new editorial was published in Oncoscience's Volume 12 on January 14, 2025, titled "Pomalidomide improved immune profiles in myeloma."

23 Jan 2025

Evaluating biomarkers for diagnosing minimal hepatic encephalopathy in cirrhotic patients

The performance of neurodegenerative biomarkers-neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1)-in diagnosing minimal hepatic encephalopathy (MHE) has not been systematically evaluated, simultaneously, nor have their associations with the development of overt hepatic encephalopathy (OHE).

17 Jan 2025

Could autophagy enhancement slow aging and combat Alzheimer's?

How cellular cleanup systems could hold the key to slowing aging and halting neurodegeneration.

9 Jan 2025

Unraveling the push-pull mechanism of neuron migration

The journey of a thousand miles begins with a single step, but for developing neurons, this first step relies on collaboration from multiple signaling pathways.

9 Jan 2025

Ketone body β-hydroxybutyrate restores protein balance and targets Alzheimer’s-linked aggregates

Scientists identify β-hydroxybutyrate as a key regulator of protein solubility, offering a novel pathway to combat neurodegeneration in aging and Alzheimer’s disease.

4 Dec 2024

Study cracks the cold case of immunotherapy resistance

A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.

3 Dec 2024

Targeting intracellular checkpoints to enhance NK cell immunotherapy

Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.

27 Nov 2024

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.

17 Nov 2024

Bioactive peptides from Chlorella vulgaris for therapeutic applications

Chlorella vulgaris is a green, photosynthetic microalga in the phylum Chlorophyta. The goal of our study was to perform a bioinformatics analysis of Photosystem I P700 chlorophyll a apoprotein A2, one of its photosynthesis-related proteins, and to hunt for potent bioactive peptides.

27 Oct 2024

New insights on protein degraders open doors to treatment for 'undruggable' diseases

Researchers at the University of Dundee have revealed in the greatest detail yet the workings of molecules called 'protein degraders' which can be deployed to combat what have previously been regarded as 'undruggable' diseases, including cancers and neurodegenerative diseases.

12 Oct 2024

International experts to gather for ALS symposium in Chicago

The 2024 Les Turner Symposium on ALS will be held on Monday, Nov. 4 in Chicago. Hosted by the Les Turner ALS Foundation and the Les Turner ALS Center at Northwestern Medicine, this event will assemble internationally-renowned ALS researchers, clinicians, advocates, and people living with ALS to discuss the latest research and perspectives on the disease.

3 Oct 2024

New study explores UBA1 dysfunction in VEXAS and cancer

A new research perspective was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "UBA1 dysfunction in VEXAS and cancer."

3 Oct 2024

COVID-19 causes lasting cognitive impairment tied to brain injury markers

Researchers found that COVID-19 patients experienced widespread cognitive deficits one year post-hospitalization, associated with elevated brain injury markers and reduced brain volume. Cognitive recovery plateaued over time, suggesting lasting impacts.

26 Sep 2024